Long-term increase in the ratio of own products to 60%
First written in FY2021. 3 of 9 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2023: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Other".
- FY2026Full-year ratio declined but remained within the target rangeAnnual report
「The proportion of in-house products fell to 56.0% (down 1.4 points year on year), while the gross profit margin declined to 59.4% (down 1.0 point year on year).」
Although it remained within the long-term target range of approximately 55–65%, the proprietary product ratio declined 1.4 percentage points from the previous fiscal year to 56.0%. - FY2026-H1Down year on year while remaining within the target rangeAnnual report
「The proprietary product ratio was 55.1%, down 2.5 percentage points year on year.」
Although the proprietary product ratio remained near the lower end of the long-term target range of approximately 55–65%, it declined 2.5 percentage points year on year to 55.1%. - FY2025-H1Within the target range but down year on yearAnnual report
「The proprietary product ratio was 57.6%, down 1.5 percentage points year on year, owing to higher sales of purchased products, including cerebrovascular products and hemostatic devices for the femoral vein.」
Although it remained within the long-term target range of approximately 55–65%, the ratio declined 1.5 percentage points year on year as sales of purchased products increased. - FY2024-Q3AdvancedAnnual report
「The proprietary product ratio rose 4.6 percentage points year on year to 59.0%.」
The proprietary product ratio, for which the long-term target is approximately 55–65%, was 59.0% for the nine months ended the third quarter, up 4.6 percentage points year on year. - FY2024-Q2AdvancedAnnual report
「The proprietary product ratio rose 5.2 percentage points year on year to 59.1%, owing to higher revenue from proprietary products as the number of AF cases increased, partly offset by lower revenue from purchased products following a change in the distribution channel for “RF Needle.”」
Against the long-term target range of approximately 55–65% for the proprietary product ratio, the ratio for the six months ended the second quarter was 59.1%, up 5.2 percentage points year on year. - FY2024-Q1AdvancedAnnual report
「The ratio of proprietary products rose 5.2 percentage points year on year to 59.8%, due to higher sales of proprietary products resulting from an increase in AF cases and lower sales of purchased products following the change in the distribution channel for RF Needle.」
In relation to the long-term target level of approximately 55% to 65% for the in-house product ratio, the ratio was 59.8% in the first quarter. - FY2023ReframedAnnual report
「Under the medium-term management plan formulated in May 2023, we set a long-term target range of approximately 55% to 65% for the in-house product ratio.」
Under the new medium-term management plan, the long-term target level was presented as a range of approximately 55% to 65%, replacing the previous long-term target of 60%. - FY2022RestatedAnnual report
「Under the medium-term management plan formulated in November 2020, we set a long-term target of achieving an in-house product ratio of 60%.」
The long-term target of an in-house product ratio of 60% was reconfirmed in the research and development policy. - FY2021First statedAnnual report
「Under the medium-term management plan formulated in November 2020, we set a long-term target of increasing the in-house product ratio to 60%.」
In addition to the medium-term plan's target of an in-house product ratio of at least 50%, the company specified for the first time a long-term target of increasing the ratio to 60%.